Neurocrine Biosciences, Inc.’s recent filing unveils that its Chief Regulatory Officer Delaet Ingrid unloaded Company’s shares for reported $37346.0 on Apr 01 ’24. In the deal valued at $137.30 per share,272 shares were sold. As a result of this transaction, Delaet Ingrid now holds 7,507 shares worth roughly $0.99 million.
Then, Delaet Ingrid sold 5,000 shares, generating $725,320 in total proceeds. Upon selling the shares at $145.06, the Chief Regulatory Officer now owns 7,507 shares.
Before that, BENEVICH ERIC sold 75,000 shares. Neurocrine Biosciences, Inc. shares valued at $10,453,417 were divested by the Chief Commercial Officer at a price of $139.38 per share. As a result of the transaction, BENEVICH ERIC now holds 40,778 shares, worth roughly $5.37 million.
A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Mizuho maintained its rating on August 21, 2023. It rated NBIX as “a Neutral”.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc. [NASDAQ:NBIX] saw its stock fall -2.17% to $131.74. Over the last five days, the stock has lost -5.52%. Neurocrine Biosciences, Inc. shares have fallen nearly -0.02% since the year began. Nevertheless, the stocks have risen 26.95% over the past one year. While a 52-week high of $148.37 was reached on 03/21/24, a 52-week low of $89.04 was recorded on 02/07/24. SMA at 50 days reached $136.72, while 200 days put it at $119.59. A total of 0.77 million shares were traded, compared to the trading of 0.58 million shares in the previous session.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 129.84, which if violated will result in even more drops to 127.94. On the upside, there is a resistance level at 135.32. A further resistance level may holdings at 138.90. The Relative Strength Index (RSI) on the 14-day chart is 36.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.96%. Stochastics %K at 12.27% indicates the stock is a buying.
